-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-521371-31-00
4
Sepsis
-
2025-522049-23-00
6
granulomatosis with polyangiitis and microscopic polyangiitis
-
2025-522176-86-01
5
Moderate Calcific Aortic Valve Stenosis (CAVS)
-
2025-522373-10-00
5
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
-
2025-522790-10-00
4
Non Small Cell Lung Cancer
-
2025-523149-80-00
10
Adult patients admitted to the ICU and receiving unplanned invasive me
-
2025-524374-42-00
4
allogeneic haematopoietic stem cell transplant recipient
-
2025-524475-23-00
5
Neisseria gonorrhoeae Infections
-
2025-524976-40-00
5
patients with influenza-induced acute hypoxemic respiratory failure
-
2025-524978-42-00
4
Asymptomatic anal LGV infection
-
2025-521038-27-00
5
2026-06-23
Immune system diseases
-
2025-521590-13-00
5
2026-05-28
Moderately to Severely Active Crohn’s Disease
-
2025-523275-27-00
5
2026-05-26
X-Linked Protoporphyria (XLP)
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-522896-27-00
4
2026-05-11
Asthma
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer
-
2024-518007-22-00
5
2025-12-05
Prevention of monkeypox (mpox) infection
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-516393-29-00
5
2024-12-03
Patients colonized with MDR-GNB
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)